ARCHIVES

FDA Accepts DCT Board’s Criteria For Approval Of New Drugs, Explains Plan for Early Action

This article is from The Cancer Letter archive.

Vol. 15 No. 07 | February 17, 1989

Download PDF Visit The Full Archive

Related Articles

Also in this 8-page issue: NIH Conflict of Interest panel recommends that NIH employees should not receive stock options or equities as compensation for outside work.

May 7, 2004

NCI Director To Decide Fate Of P-4 After NCAB Meeting In June.

April 20, 2007

Adcetris Granted Approval For Hodgkin’s Lymphoma and ALCL

September 30, 2011

In Brief: Big Ten Cancer Research Consortium Names Executive Officer

May 30, 2014

Human Protein Index Stirs NCI, NCAB Interest, Fires Up Growing Controversy

August 7, 1981

Award Fees Show House NCI thinks FCRF Contractors Are Performing

August 15, 1986